1. Home
  2. ONL vs HUMA Comparison

ONL vs HUMA Comparison

Compare ONL & HUMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Orion Office REIT Inc.

ONL

Orion Office REIT Inc.

HOLD

Current Price

$2.15

Market Cap

165.4M

Sector

Real Estate

ML Signal

HOLD

Logo Humacyte Inc.

HUMA

Humacyte Inc.

HOLD

Current Price

$0.41

Market Cap

165.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ONL
HUMA
Founded
2021
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
165.4M
165.7M
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
ONL
HUMA
Price
$2.15
$0.41
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
★ $1.63
AVG Volume (30 Days)
318.0K
★ 5.8M
Earning Date
11-05-2026
11-11-2026
Dividend Yield
★ 3.70%
N/A
EPS Growth
N/A
★ 79.37
EPS
★ 0.19
N/A
Revenue
★ $147,647,000.00
$2,038,000.00
Revenue This Year
$1.67
$72.32
Revenue Next Year
$0.11
$518.79
P/E Ratio
$11.32
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$1.89
$0.34
52 Week High
$3.05
$1.78

Technical Indicators

Market Signals
Indicator
ONL
HUMA
Relative Strength Index (RSI) 38.23 36.62
Support Level $2.02 $0.34
Resistance Level $2.59 $0.75
Average True Range (ATR) 0.08 0.04
MACD 0.00 0.00
Stochastic Oscillator 41.49 39.45

Price Performance

Historical Comparison
ONL
HUMA

About ONL Orion Office REIT Inc.

Orion Properties Inc is an internally managed real estate investment trust engaged in the ownership, acquisition, and management of a diversified portfolio of office properties located in high-quality suburban markets across the United States and leased mainly on a single-tenant net lease basis to creditworthy tenants. Its portfolio is comprised of traditional office properties, as well as governmental, medical office, flex/laboratory, and R&D and flex/industrial properties. The company is focused on shifting its portfolio concentration over time away from traditional office properties, towards more dedicated use assets with specialized uses that include an office component. It operates in one business segment: commercial real estate.

About HUMA Humacyte Inc.

Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.

Share on Social Networks: